Veconomist the Vegan Business Magazine Stay Informed Stay Competative Get our Newsletter
advertisement

« Previous article
IFF Highlight Compre...

8th May 2024  Editorial by: newprotein staff writer

21st.BIO Unveils a New Pilot Plant Facility to Accelerate Impact of Biotech Innovations Globally


  • Combining world-class industrially proven technology with fermentation capacity, 21st.BIO helps customers get to scale faster, in a risk-mitigated and cost-effective way.
  • Margrethe Vestager, Executive Vice President of the European Commission, was onsite to inaugurate the pilot facility and underlined the high potential of the biotech sector to address key challenges ranging from ensuring sustainability to stabilizing global food chains.

21st.BIO has unveiled a new pilot plant facility in its Danish headquarters, designed to support companies in upscaling their bioproduction.

21st.BIO offers this pilot facility to the market to facilitate and accelerate the step between internal lab-scale fermentation and large-scale production. 21st.BIO’s pilot construction and deep experience are ideal to define the important parameters and equipment needed for optimal large-scale production of proteins via fermentation. This will, on top of the best fermentation protocols, for example also help customers select the best CMO for individual project needs and limit the risk of costly failures.

With over 3000 liters of fermentation capacity, the facility offers a full range of capabilities, equipment, and competences to help customers optimize their own specific processes. The pilot plant is focused on scaling up the production of recombinant proteins and peptides with applications in nutrition, food and beverages, agriculture, biomaterials, and biopharma.

The pilot plant is designed to enable strong collaboration between 21st.BIO and customer teams during scaling. The facility is strategically located in the same building as the company’s strain development laboratories, allowing for joint work on further improving the customers’ production strains and fermentation processes.

21st.BIO’s pilot welcomes established industry leaders in ingredient manufacturing as well as early-stage startups.

In January this year, 21st.BIO granted ingredient manufacturers access to its precision fermentation technology platform, enabling the production of dairy proteins at competitive cost.

Read the full story here or contact 21st.BIO today using the green "Request Information" button below.


    

Tags:

Date Published: 8th May 2024

Source article link: View


View full company details


Related news